



Zai Lab to Announce Full Year 2018 Financial Results

2019年 2月 21日

SHANGHAI, China, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and US-based innovative commercial stage biopharmaceutical company, today announced that it will release its full year 2018 financial results before the market opens on Thursday, March 7th, 2019 and host a conference call at 8:30am ET to discuss financial results for the full year ended December 31, 2018. On the call, Zai Lab's senior management team will also provide an update on the Company's business and upcoming milestones.

The live webcast and a replay may be accessed by visiting the Company's website at <http://ir.zailaboratory.com>. Alternatively, please call (866) 394-4355 (U.S.), (314) 888-4344 (International), 800966253 (Hong Kong) or 4006828609 (China) to listen to the live conference call. The conference ID number for the live call is 6980867. Please dial in approximately 10 minutes prior to the call. Telephone replay will be available approximately two hours after the call. To access the replay, please call (855) 859-2056. The conference ID number for the replay is 6980867.

About Zai Lab

Zai Lab (NASDAQ: ZLAB) is a China and US-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China's pharmaceutical market and addressing unmet medical needs. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.

For more information, please contact:

ZAI LAB CONTACTS:

Zai Lab

Billy Cho, CFO

+86 137 6151 2501

billy.cho@zailaboratory.com

Media: Nancie Steinberg / Robert Flamm, Ph.D.

Burns McClellan, on behalf of Zai Lab

212-213-0006

nsteinberg@burnsmc.com / rflamm@burnsmc.com

Investors: Jill Steier

Burns McClellan, on behalf of Zai Lab

212-213-0006

jsteier@burnsmc.com



Source: Zai Lab Limited